Methylprednisolon Ace Pharmaceuticals (Methylprednisolone)

Methylprednisolone is a glucocorticoid that modulates inflammatory and immune pathways across several disease groups.

• Acute exacerbations of asthma and COPD: reduces airway inflammation and improves breathing.
• Severe allergic reactions: rapidly diminishes hypersensitivity and tissue swelling.
• Rheumatic and musculoskeletal disorders: alleviates joint pain, swelling and stiffness.
• Dermatologic inflammatory conditions: controls skin inflammation and lesion formation.

• Methylprednisolone diffuses across cell membranes and binds intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus, where it binds glucocorticoid response elements and alters transcription of multiple genes, leading to decreased production of pro‑inflammatory cytokines, inhibition of leukocyte migration, and suppression of immune cell activation.

Methylprednisolone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Increased blood glucose levels.
• Insomnia or sleep disturbances.
• Mood swings, anxiety or mild depression.
• Gastrointestinal discomfort, including nausea or dyspepsia.
• Weight gain and fluid retention.
• Skin thinning or easy bruising.

Serious or Rare Side Effects

• Adrenal insufficiency on abrupt discontinuation.
• Severe infections due to immunosuppression.
• Osteoporosis or pathological fractures.
• Psychosis or severe mood disorders.
• Hypercortisolism manifestations such as Cushingoid appearance.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Assess infection risk: screen for active or latent infections before use.
• Monitor blood glucose: adjust diabetic therapy as needed.
• Screen for osteoporosis: consider bone density testing in long‑term users.
• Use the lowest effective dose: limit duration to reduce systemic exposure.
• Taper when stopping: gradually reduce dose to avoid adrenal crisis.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Methylprednisolone can alter the pharmacokinetics or pharmacodynamics of several co‑administered agents.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may markedly increase systemic steroid levels.
• Live vaccines: heightened risk of disseminated infection.
• Anticoagulants (e.g., warfarin): potentiation of anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely)

• Antidiabetic drugs: may require dose reduction due to hyperglycaemic effect.
• NSAIDs or other ulcerogenic agents: increased gastrointestinal bleeding risk.
• Non‑live vaccines: possible reduced immunogenic response.
• Diuretics: may exacerbate electrolyte disturbances.
• Antiretrovirals (e.g., protease inhibitors): may affect steroid metabolism.